SEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI IL-5 ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA
|
|
- Amanda McCormick
- 5 years ago
- Views:
Transcription
1 SEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA FIND OUT MORE VISIT - Vial not actual size FOR HEALTHCARE PROFESSIONALS This information has been produced and developed by GlaxoSmithKline. UK/NLA/0012/15(1)a Date of preparation: March 2016 Prescribing information can be found on the penultimate page of this document. TARGETED ANTI THERAPY
2 2 DISEASE OVERVIEW ASTHMA Asthma is a chronic heterogeneous lung disease characterised by airway inflammation, bronchial hyperresponsiveness, and reversible airway obstruction that fluctuates over time. 1,2 The majority of asthma patients are adequately controlled and treated in a stepwise approach as recommended by the British Thoracic Society/Scottish Intercollegiate Guideline Network (BTS/SIGN). 3 SEVERE ASTHMA The international European Respiratory Society (ERS) and American Thoracic Society (ATS) Task Force defined severe asthma as: asthma which requires treatment with high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy. 4 REFRACTORY ASTHMA A small proportion of patients with asthma have refractory disease, which either remains uncontrolled despite their treatment being optimised or requires high doses of controller and reliever medication to maintain symptom control. 5 PHENOTYPES Evidence shows that patients with severe asthma are comprised of different phenotypes; one example is an eosinophilic asthma phenotype which has been shown to be associated with asthma severity, late onset disease and steroid refractoriness. 2 TARGETED THERAPIES By characterising patients severe asthma phenotypes they can be differentially treated with personalised and targeted therapies, and outcomes could be improved. 6
3 3 BURDEN It is estimated that 5 10% of the total asthma population have severe asthma. 4 Severe asthma patients are at high risk of having a severe exacerbation and are often dependent on oral corticosteroids (OCS). 6 These patients account for a significant percentage of healthcare resource utilisation 4 and have few therapeutic options available. 5,6 Severe asthma patients may face a number of additional costs including lost earnings due to impaired productivity and/or reduced quality of life. 7,8 OCS can have significant side-effects and co-morbidities that result in a burden on patients lives and NHS services. These include osteoporosis (fracture risk), diabetes and cataracts. 9 The adherence to daily OCS has been documented to be as low as 45%. 10,11 INTRODUCING NUCALA 100MG SC A TARGETED ADD-ON THERAPY FOR ADULT PATIENTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA NUCALA 100MG SC COMPARED TO PLACEBO, WHEN BOTH ARE ADDED TO STANDARD OF CARE: Significantly reduces frequency of exacerbations by 53% 12 Significantly reduces patients dependency on OCS whilst maintaining asthma control 13 Improves health-related quality of life 12 NUCALA IS GENERALLY WELL TOLERATED. THE MOST COMMONLY REPORTED ADVERSE REACTIONS WERE HEADACHE, INJECTION SITE REACTIONS AND BACK PAIN. Vial not actual size Standard of care High dose ICS and additional maintenance treatment(s), in line with BTS/SIGN Step 4 and above
4 4 INTERLEUKIN-5 is the major cytokine responsible for the growth, differentiation, recruitment, activation and survival of eosinophils. 14 Eosinophils play a role in maintaining long-term inflammation and exacerbation risk, under the control of. 15 INFLAMMATORY PATHWAY FOCUSING ON STEPS ALLERGENS POLLUTANTS, PATHOGENS Th2 ILC2 IgE B CELLS EOSINOPHILS Recruitment, activation, survival of eosinophils by pathways MAST CELLS T-Helper 2 cells (Th2); Group 2 Innate Lymphoid Cells (ILC2); Interleukin-5 (); Immunoglobulin E (IgE)
5 5 NUCALA 100MG SUBCUTANEOUS INJECTION Nucala is the first humanised monoclonal antibody (IgG1 Kappa) that inhibits the bioactivity of with high affinity and specificity. Nucala inhibits signalling by blocking binding to the alpha chain of the receptor complex. This in turn inhibits signalling and the production and survival of eosinophils, thereby reducing inflammation. Following a dose of Nucala 100mg SC every 4 weeks for 32 weeks, blood eosinophil levels were reduced by 84%* when compared with placebo when both were added to standard of care. This reduction was observed within 4 weeks of treatment. 16 *blood eosinophils were reduced from a geometric mean count at baseline of 290 to 40 cells/µl at week 32, n=182 HOW DOES NUCALA WORK? NUCALA R EOSINOPHIL PROLIFERATION MATURATION SURVIVAL Standard of care - High dose ICS and additional maintenance treatment(s), in line with BTS/SIGN Step 4 and above
6 6 REFERENCES 1. Shifren A, Witt C, Christie C et al. Mechanisms of remodelling in asthmatic airways. J Allergy Walford H and Doherty T. Diagnosis and management of eosinophilic asthma: A US perspective. J Asthma Allergy 2014; 11 (7): Scottish Intercollegiate Guideline Network and the British Thoracic Society. British Guideline on the management of asthma (last accessed 02 September 2015). 4. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43 (2): Peters SP, Ferguson G, Deniz Y et al. Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100: Campo P, Rodriguez F, Sánchez-García S et al. Phenotypes & endotypes of uncontrolled severe asthma: New treatments. J Investig Allergol Clin Immunol 2013; 23 (2): Gibeon D, Heaney LG, Brightling CE et al., Dedicated severe asthma services improve healthcare utilisation and quality of life. Chest 2015 doi: /chest [EPub ahead of print] 8. O Neill S, Sweeney J, Paterson CC et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Online Supplementary Information; Available from DC1/thoraxjnl supp.pdf (last accessed 09 September 2015). 9. Liu D, Ahmet A, Ward L et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013; 9 (1): Gamble J, Stevenson M, McClean E et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180 (9): Robinson DS, Campbell DA, Durham SR et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22 (3): Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371 (13): Garcia G, Taillé C, Laveneziana P et al. Anti-interleukin-5 therapy in severe asthma. Eur Resp Rev 2013; 22 (129): Malinovschi A, Fonseca JA, Jacinto T et al. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013; 132 (4): Nucala Summary of Product Characteristics, 2015.
7 7 PRESCRIBING INFORMATION Nucala (mepolizumab) Prescribing information (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) Nucala (mepolizumab) powder for solution for injection. Each vial contains 100 mg mepolizumab. After reconstitution, each ml of solution contains 100 mg mepolizumab. Indications: Indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients. Dosage and administration:nucala should be prescribed by physicians experienced in the diagnosis and treatment of severe refractory eosinophilic asthma. Adults: Recommended dose of mepolizumab is 100 mg administered subcutaneously once every 4 weeks. Treatment is intended long-term and the need for continued therapy should be considered at least on an annual basis. Method of administration is subcutaneous only, administered by a healthcare professional. It may be injected into the upper arm, thigh, or abdomen. The powder should be reconstituted under aseptic conditions and administered within 8 hours, protected from sun light, at <30 degrees Celsius. Contraindications: Hypersensitivity to the active substances or to any of the excipients (sucrose, sodium phosphate dibasic heptahydrate and polysorbate 80). Precautions: Not to be used to treat acute asthma exacerbations. Asthma related adverse events or exacerbations may occur during treatment. Abrupt discontinuation of corticosteroid after initiation of therapy is not recommended. Hypersensitivity and administration-related reactions may occur within hours of administration, but some instances may have a delayed onset. Pre-existing helminth infections should be treated before commencing Nucala. Special populations: No dose adjustment is required for elderly, hepatic impaired and renal impaired patients with a CrCl 50-80ml/min (limited data for patients with CrCl <50ml/min). Interactions with other medicinal products: No interaction studies have been performed. The potential for interactions is considered low. Pregnancy and breast-feeding: Experience limited. Balance risks against benefits. Side effects: Very Common ( 1/10): Headache. Common ( 1/100 to <1/10): Lower respiratory tract infection, urinary tract infection, pharyngitis, hypersensitivity reactions, nasal congestion, abdominal pain upper, eczema, back pain, administration related reactions (rash, flushing, myalgia), local injection site reactions, pyrexia. Immunogenicity: In trials 15/260 patients (6%) developed anti-mepolizumab antibodies. Neutralising antibodies were detected in just 1 subject. See SmPC for other side effects. Legal category: POM. Presentation and Basic NHS cost: Nucala. 1 vial Marketing authorisation (MA) no. [EU/1/15/1043/001]; MA holder: GlaxoSmithKline Trading Services Limited, Currabinny, Carrigaline, County Cork, Ireland. Last date of revision: November UK/NLA/0013/15. Nucala is a registered trademark of the GlaxoSmithKline group of companies. All rights reserved. group of companies. All rights reserved. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to GlaxoSmithKline on TARGETED ANTI THERAPY
8 8 INTRODUCING NUCALA 100MG SUBCUTANEOUS (SC) NUCALA IS THE FIRST TARGETED ANTI ADD-ON THERAPY FOR ADULT PATIENTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA BRAND NAME Nucala GENERIC NAME LICENSED INDICATION THERAPEUTIC CLASS ANTICIPATED PLACE IN THERAPY (BTS/SIGN GUIDELINES*) DOSAGE ADMINISTRATION DURATION OF TREATMENT KEY CLINICAL TRIALS SAFETY Mepolizumab An add-on treatment for adult patients with severe refractory eosinophilic asthma Humanised monoclonal antibody which inhibits the bioactivity of the cytokine interleukin-5 () Nucala-eligible patients are either at step 4 and remain uncontrolled despite being on high dose inhaled corticosteroid (ICS) plus additional maintenance treatment(s), or at step 5 100mg for subcutaneous injection once every 4 weeks To be reconstituted under aseptic conditions and administered subcutaneously by a healthcare professional Intended for long-term treatment. The need for continued therapy should be considered at least on an annual basis MENSA: Exacerbation reduction study. Mepolizumab as adjunctive therapy in patients with severe asthma SIRIUS: Steroid reduction with mepolizumab study DREAM Phase IIb/III dose ranging study that defined a responder population by blood eosinophil count that was studied in phase III Nucala is generally well tolerated; the most commonly reported adverse reactions were headache, injection site reactions and back pain *BTS - British Thoracic Society; SIGN - Scottish Intercollegiate Guideline Network
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationTraiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
More informationNUCALA is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients
QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 100 mg mepolizumab. After reconstitution, each ml of solution contains 100 mg mepolizumab. Mepolizumab is a humanised monoclonal antibody (IgG1,
More informationTargeting Interleukin-5 in Patients With Severe Eosinophilic Asthma: A Clinical Review
Targeting Interleukin-5 in Patients With Severe Eosinophilic Asthma: A Clinical Review Christine Lam, PharmD, BCPS; Kunal J. Shah, PharmD; and Rupal Mansukhani, PharmD INTRODUCTION Asthma is a chronic
More informationStudy Investigators/Centers: GSK sponsored studies MEA112997, MEA115588, and MEA and a proof of concept investigator sponsored study CRT110184
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTechnology appraisal guidance Published: 25 January 2017 nice.org.uk/guidance/ta431
Mepolizumab for treating severeere refractory eosinophilic asthma Technology appraisal guidance Published: 25 January 2017 nice.org.uk/guidance/ta431 NICE 2017. All rights reserved. Subject to Notice of
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la] Mepolizumab for Injection
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] Mepolizumab for Injection Read this carefully before you start taking NUCALA and each time you
More informationCHALLENGES OF REAL LIFE ASTHMA MANAGEMENT. Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board
CHALLENGES OF REAL LIFE ASTHMA MANAGEMENT Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board CONFLICT OF INTEREST Employee of Auckland District Health
More informationMepolizumab is a humanised monoclonal antibody (IgG1, kappa), which targets human
NUCALA PRODUCT INFORMATION N A M E OF THE MEDICINE The active ingredient of NUCALA is mepolizumab. Structure of mepolizumab: CAS number: 196078-29-2 DESCRIPTION Mepolizumab is a humanised monoclonal antibody
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationDifferent kinds of asthma, different kinds of therapies
Different kinds of asthma, different kinds of therapies Friday 10 th November 2017 XXXIII Congresso Sezione SIAAIC Toscana Professor Neil Barnes Medical Head Global Respiratory Franchise, GSK Brentford,
More informationSwiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab)
Swiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab) RMP Summary: Version 1, March 2017 EU RMP: Version 2, 26.5.2016 The Risk Management Plan (RMP) is a comprehensive document submitted
More informationLocal Omalizumab Treatment Protocol (For children 6 to <12 years of age)
Local Omalizumab Treatment Protocol (For children 6 to
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationNucala (mepolizumab) Prior Authorization Protocol
Nucala (mepolizumab) Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationCinqair. (reslizumab) New Product Slideshow
Cinqair (reslizumab) New Product Slideshow Introduction Brand name: Cinqair Generic name: Reslizumab Pharmacological class: Interleukin-5 antagonist Strength and Formulation: 100mg/10mL; solution for IV
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME NUCALA mepolizumab 100 mg vials (100 mg/ml after reconstitution). 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial delivers mepolizumab 100 mg (100 mg/ml after
More informationNUCALA. mepolizumab. Patient Support
NUCALA mepolizumab Patient Support This booklet has been developed by GSK UK/NLA/0007/15(1) Date of preparation: November 2016 INTRODUCTION This informative guide is for people who have been prescribed
More informationCost-effectiveness of mepolizumab (Nucala ) as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
Cost-effectiveness of mepolizumab (Nucala ) as an add-on treatment for severe refractory eosinophilic asthma in adult patients. The NCPE has issued a recommendation regarding the cost-effectiveness of
More informationHorizon Scanning Centre May Mepolizumab for severe refractory eosinophilic asthma first line SUMMARY NIHR HSC ID: 1643
Horizon Scanning Centre May 2014 Mepolizumab for severe refractory eosinophilic asthma first line SUMMARY NIHR HSC ID: 1643 This briefing is based on information available at the time of research and a
More informationNUCALA 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
NUCALA Mepolizumab 1. NAME OF THE MEDICINAL PRODUCT NUCALA, powder for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 100 mg mepolizumab. After reconstitution, each
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr NUCALA mepolizumab lyophilized powder for subcutaneous injection 100 mg/ml Interleukin-5 (IL-5) inhibitor GlaxoSmithKline Inc. 7333 Mississauga
More informationSummary of the risk management plan (RMP) for Nucala (mepolizumab)
EMA/671186/2015 Summary of the risk management plan (RMP) for Nucala (mepolizumab) This is a summary of the risk management plan (RMP) for Nucala, which details the measures to be taken in order to ensure
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS ---------------------- These highlights do not include all the information needed to use NUCALA safely and effectively.
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NUCALA safely and effectively. See full prescribing information for NUCALA. NUCALA (mepolizumab)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationSingle Technology Appraisal (STA) Benralizumab for treating severe asthma
Single Technology Appraisal (STA) Benralizumab for treating severe asthma Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments received
More informationMonoclonal antibody therapy for severe asthma
INFORMATION PAPER FOR PRIMARY HEALTHCARE PROFESSIONALS MONOCLONAL ANTIBODY THERAPY Monoclonal antibody therapy for severe asthma KEY POINTS Benralizumab, mepolizumab and omalizumab are monoclonal antibody
More informationNational Horizon Scanning Centre. Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids.
Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids May 2008 This technology summary is based on information available at the time of research and a limited
More informationPolicy Effective 4/1/2018
Corporate Medical Policy Interleukin-5 Antagonists Notification File Name: Origination: Last CAP Review: Next CAP Review: Last Review: interleukin_5_antagonists 2/2016 11/2017 11/2018 2/2018 Policy Effective
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationTo report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NUCALA safely and effectively. See full prescribing information for NUCALA. NUCALA (mepolizumab)
More informationDedicated Severe Asthma Services Improve Health-care Use and Quality of Life
[ Original Research Asthma ] Dedicated Severe Asthma Services Improve Health-care Use and Quality of Life David Gibeon, MBChB ; Liam G. Heaney, MD ; Chris E. Brightling, PhD, FCCP ; Rob Niven, MD ; Adel
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationIntroduction Mepolizumab (Nucala) is indicated as an add-on therapy for people with severe refractory eosinophilic asthma, aged 12 years.
Clinical Recommendations For The Use Of Mepolizumab In Severe Asthma Clinical Recommendations For The Use Of Mepolizumab In Severe Asthma... 1 About the treatment... 1 Introduction... 1 Mechanism of action...
More informationCTAF Overview. Agenda. Evidence Review. Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia
CTAF Overview Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia February 12, 2016 Core program of the Institute for Clinical and Economic Review (ICER) Goal:
More informationIndirect Comparison of Dupilumab and Mepolizumab Treatments for Uncontrolled Eosinophilic Asthma Bayesian Analysis of Randomized Controlled Trials
Showa Univ J Med Sci 30 2, 189 196, June 2018 Original Indirect Comparison of Dupilumab and Mepolizumab Treatments for Uncontrolled Eosinophilic Asthma Bayesian Analysis of Randomized Controlled Trials
More informationOmalizumab vs. Mepolizumab for Asthma Patients: How to Decide. Indications
vs. for Asthma Patients: How to Decide Indications Asthma is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity
More informationBiologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks
Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope June 13, 2018 Background The Centers for
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationBOLSTRAN Injection (Omalizumab)
Published on: 27 Feb 2017 BOLSTRAN Injection (Omalizumab) Composition Active Substance Omalizumab is a humanized monoclonal antibody manufactured from a mammalian cell line. One vial of BOLSTRAN 150 mg
More informationSevere Asthma(s): Can THEY be prevented or reversed?
Severe Asthma(s): Can THEY be prevented or reversed? Sally Wenzel, MD Professor of Medicine UPMC Chair in Translational Airway Biology Disclosures Sally Wenzel, M.D. Grant/Research Support: Boehringer-Ingelheim,
More informationWEBINAR. Difficult-to-treat and severe asthma: changing the paradigm
WEBINAR Difficult-to-treat and severe asthma: changing the paradigm A multidisciplinary discussion on new therapies, and how to identify and manage difficult-to-treat and severe asthma DIFFICULT-TO-TREAT
More informationDisclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine
Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Injectable Asthma Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Injectable Asthma Agents Xolair (omalizumab) Prime Therapeutics will
More informationWhat s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals
What s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals Asthma is an inflammatory disease Relaxed smooth muscles Air trapped in alveoli Tightened
More informationSevere Asthma & Exacerbations: Dawn of a New Era?
Severe Asthma & Exacerbations: Dawn of a New Era? Christophe von Garnier Department of Pulmonary Medicine Syndromes, Phenotypes & Endotypes Asthma Syndrome Variable symptoms, expiratory airflow limitation,
More informationDistinguishing Type-2 Asthma
UPDATE ON ASTHMA THERAPY: MATCHING PHENOTYPE TO TREATMENT Sally E. Wenzel, MD Professor of Medicine University of Pittsburgh Asthma Institute@UPMC Subsection Chief of Allergy 1234567 891234 567891 2345678
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationReview. Key words : asthma, benralizumab, interleukin-5, mepolizumab, reslizumab. Introduction
Showa Univ J Med Sci 30 1, 11 25, March 2018 Review Comparative Efficacy and Safety of Anti-Interleukin-5 Therapies and Placebo in Patients with Uncontrolled Eosinophilic Asthma : A Systematic Review and
More informationPredicting response to triamcinolone in severe asthma by machine learning: solving the Enigma
Page 1 of 5 Predicting response to triamcinolone in severe asthma by machine learning: solving the Enigma Kian Fan Chung National Heart & Lung Institute, Imperial College London & Royal Brompton and Harefield
More informationNucala. Nucala (mepolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.07 Subject: Nucala Page: 1 of 5 Last Review Date: December 2, 2016 Nucala Description Nucala (mepolizumab)
More informationIL-5 Antagonists (IgG1 kappa) Fasenra (benralizumab) Nucala (mepolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.07 Subject: IL-5 Antagonists (IgG1 kappa) Page: 1 of 6 Last Review Date: June 22, 2018 IL-5 Antagonists
More informationSteps to better understand severe asthma in adults
PRESCRIBING IN PRACTICE n Steps to better understand severe asthma in adults Alexandra M Nanzer MRCP and Andrew Menzies-Gow PhD, MB BS Primary care plays an essential role in identifying and supporting
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationBronchial Thermoplasty For Severe Persistent Asthma
Bronchial Thermoplasty For Severe Persistent Asthma Faisal Khan MD Center For Respiratory and Sleep Medicine Indiana Internal Medicine Consultants Franciscan Saint Francis hospital Agenda Burden of Severe
More informationAsthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient
Asthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient Mario Castro MD, MPH Asthma & Airway Translational Research Unit Washington University School of Medicine St.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationSystems Pharmacology Respiratory Pharmacology. Lecture series : General outline
Systems Pharmacology 3320 2017 Respiratory Pharmacology Associate Professor Peter Henry (Rm 1.34) Peter.Henry@uwa.edu.au Division of Pharmacology, School of Biomedical Sciences Lecture series : General
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
NUCALA (mepolizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationJamie Lee Memorial Lecture ( ) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab
Jamie Lee Memorial Lecture (1958-2017) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab Larry Borish, M.D. Professor of Medicine and Microbiology University of Virginia Conflict of Interest
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Asthma Education Day Thursday, October 30, 2014 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry Ford Hospital
More informationPre-administration checklist for Fluenz Tetra nasal spray vaccine
Pre-administration checklist for Fluenz Tetra nasal spray vaccine This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare
More informationClinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:
Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMepolizumab (asthma)
IQWiG Reports Commission No. A16-33 Mepolizumab (asthma) Addendum to Commission A16-03 1 Addendum Commission:A16-33 Version: 1.0 Status: 29 June 2016 1 Translation of addendum A16-33 Mepolizumab (Asthma)
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationNucala (mepolizumab injection for subcutaneous use)
Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationAnnex II. Scientific conclusions
Annex II Scientific conclusions 5 Scientific conclusions Beclometasone dipropionate (BDP) is a glucocorticoid and a prodrug of the active metabolite, beclometasone-17-monopropionate. Beclometasone dipropionate
More informationWhich asthma patient has allergic airway inflammation?
Which asthma patient has allergic airway inflammation? C o n t r o l l i n g A l l e r g i c A s t h m a Several underlying diseases can present symptoms similar to asthma. Therefore, a correct diagnos
More informationjournal of medicine The new england Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma Abstract
The new england journal of medicine established in 1812 september 25, 2014 vol. 371 no. 13 Oral Glucocorticoid-Sparing Effect of in Eosinophilic Asthma Elisabeth H. Bel, M.D., Ph.D., Sally E. Wenzel, M.D.,
More informationTreatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology
Treatment Options for Complicated/Severe Asthma Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology www.kallergy.com 913-451-8555 Asthma Epidemiology World Health Organization, Asthma is one of the
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationPersonalised medicine in asthma: time for action
SERIES PERSONALISED MEDICINE Personalised medicine in asthma: time for action Kian Fan Chung 1,2 Number 1 in the Series Personalised medicine in respiratory diseases Edited by Renaud Louis and Nicolas
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationThe only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2
The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2 Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate-to-severe
More informationAre emerging PGD2 antagonists a promising therapy class for treating asthma?
Expert Opinion on Emerging Drugs ISSN: 1472-8214 (Print) 1744-7623 (Online) Journal homepage: http://www.tandfonline.com/loi/iemd20 Are emerging PGD2 antagonists a promising therapy class for treating
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Michigan Society for Respiratory Care Monday, October 5, 2015 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry
More informationThe Pharmacist s Role in Managing Severe Asthma. This activity is supported by an educational grant from Genentech. Educational Objectives
The Pharmacist s Role in Managing Severe Asthma Jennifer M. Malinowski, PharmD, RPh Assistant Dean, Academic Affairs Associate Professor, Pharmacy Practice Wilkes University School of Pharmacy Wilkes-Barre,
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More information2012/13 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)
A3D3 2012/13 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL) SECTION B PART 1 - SERVICE SPECIFICATIONS Service Specification No.
More informationTechnology appraisal guidance Published: 4 October 2017 nice.org.uk/guidance/ta479
Reslizumab for treating severeere eosinophilic asthma Technology appraisal guidance Published: 4 October 2017 nice.org.uk/guidance/ta479 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationCinqair (reslizumab injection for intravenous use)
Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationManagement of Severe Asthma Including Biologics and Bronchial Thermoplasty. Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC
Management of Severe Asthma Including Biologics and Bronchial Thermoplasty Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC Disclosures ALK speaker Monaghan Medical Corporation speaker Novartis speaker
More informationTreating the right patient with the right
Asthma Getting it Right. Diagnosis, phenotypes, guidelines Treating the right patient with the right treatment Rama Vancheeswaran, FRCP, MSc Immunology, PhD Royal Free Hospital NHS Trust (Barnet site)
More informationRecent changes in the drug treatment of allergic asthma
DRUG THERAPIES IN Clinical Medicine 2013, Vol 13, No 5: 477 81 Recent changes in the drug treatment of allergic asthma David Gibeon and Andrew Menzies-Gow ABSTRACT Asthma is a heterogeneous condition with
More informationComplements asthma therapy NOT a CURE for Severe. Non pharmacologic treatment of asthma. limits the ability of the airways to constrict.
Bronchial Thermoplasty Karla Provost Pulmonary and Critical Care Medicine 2015 What is Bronchial Thermoplasty Non pharmacologic treatment of asthma Outpatient procedure performed over 3 treatment sessions
More informationWhat is Severe Persistent Asthma? What is Bronchial Thermoplasty Non pharmacologic treatment of asthma
Objectives BT defined What is Severe Persistent Asthma Case Study introduction How is BT performed Pre-op, PACU and Discharge care Who does it work for the criteria for BT Brief overview of BT results
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More information